ReviewJournal of personalized medicine2022
Multiple Sclerosis and Autoimmune Comorbidities.
Review in Journal of personalized medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 30 citations in OpenAlex.
- Multiple sclerosis and autoimmunity: a reappraisal of the evidence.Frontiers in immunology · 2026Review
- Article
- Prevalence, comorbidities, and disease-related complications of rheumatoid arthritis in Colombia: a national cross-sectional study based on administrative claims data.Advances in rheumatology (London, England) · 2025Observational
- Erratum: Characteristics and Comorbidities Influencing Mortality Risk Among Hereditary Angioedema Patients.Journal of health economics and outcomes research · 2025Article
- Cell-Free DNA, a Noninvasive Biomarker for Prediction and Detection of Neurodegenerative Diseases, New Insights, and Perspectives.CNS & neurological disorders drug targets · 2025Review
- Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study.European journal of neurology · 2025Observational
- A Literature Review and Meta-Analysis on the Potential Use of miR-150 as a Novel Biomarker in the Detection and Progression of Multiple Sclerosis.Journal of personalized medicine · 2024Review
- Prevalence of Multiple Sclerosis in Vitiligo Patients and Their First-Degree Relatives: Two Diseases with Similarities in Pathogenesis and Treatment.Dermatology practical & conceptual · 2024Article
- Article
- Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions.Acta neuropathologica · 2024Article
- Challenges in Diagnosis and Therapeutic Strategies in Late-Onset Multiple Sclerosis.Journal of personalized medicine · 2024Review
- Coexistence of multiple sclerosis and systemic lupus erythematosus - a case report.Postepy psychiatrii neurologii · 2024Article
- Exploring the shared gene signatures and mechanism among three autoimmune diseases by bulk RNA sequencing integrated with single-cell RNA sequencing analysis.Frontiers in molecular biosciences · 2024Article
- Global perspectives on the contribution of B cells to multiple sclerosis: an in-depth examination and evaluation.Frontiers in immunology · 2024Review
- The fluctuations of expression profiles of critical genes in the miRNA maturation process and pro-and anti-inflammatory cytokines in the pathogenesis and progression of multiple sclerosis.Molecular biology reports · 2023Article
- The Importance of Managing Modifiable Comorbidities in People with Multiple Sclerosis: A Narrative Review.Journal of personalized medicine · 2023Review
- The State of the Art of Pediatric Multiple Sclerosis.International journal of molecular sciences · 2023Review
- Epidemiological and Immune Profile Analysis of Italian Subjects with Endometriosis and Multiple Sclerosis.Journal of clinical medicine · 2023Article
- Personalized and Precision Medicine 2022.Journal of personalized medicine · 2023Article
- Association of autoimmune comorbidities in persons with multiple sclerosis from a population-based study with genetic linkage.Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system characterized by broad inter- and intraindividual heterogeneity and different prognoses. Multisystem comorbidities are frequent features in people with MS (PwMS) and can affect treatment choices, quality of life, disability and mortality. In this scenario, autoimmune comorbidities play a cardinal role for several reasons, such as the implication on MS pathogenesis, diagnostic delay, disease activity, disability progression, brain atrophy, and treatment choice. However, the impact of an autoimmune comorbid condition on MS is not fully elucidated. This review aims to summarize the currently available data on the incidence and prevalence of autoimmune diseases in PwMS, the possible effect of this association on clinical and neuroradiological MS course and its impact on treatment choice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.